Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.
Suggested remit: To appraise the clinical and cost effectiveness of Inhaled Treprostinil within its marketing authorisation for treating lung disease.
Zacks.com on MSN6d
Merck Halts Second PAH Drug Study Early on Strong Efficacy ResultsMerck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise ...
In a report released on January 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback